Literature DB >> 6132473

Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?

C Fischer, U Klotz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6132473     DOI： 10.1097/00007691-198004000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN： 0163-4356            Impact factor:   3.681


× No keyword cloud information.
  5 in total

1.  Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1985-12       Impact factor: 19.103

2.  The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.

Authors:  W M Awni; R A Braeckman; C S Locke; L M Dubé; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

Authors:  A K Azadkhan; S C Truelove; J K Aronson
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

5.  Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.

Authors:  P Miner; S Hanauer; M Robinson; J Schwartz; S Arora
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.